An in vivo study of the dopaminergic receptors in the brain of man using 11C-pimozide and positron emission tomography

Positron emission tomography was used to establish the regional cerebral pharmacokinetics of a carbon 11-labelled neuroleptic, pimozide, in an attempt to observe its specific bonding to dopaminergic receptors in vivo. The 11C-pimozide kinetics were compared in two brain structures at the two ends of the dopaminergic receptor density scale: the striatum and cerebellum, very rich in and devoid of these receptors respectively. In 8 patients a significant radioactivity uptake was observed in the striatum as compared with the cerebellum, in agreement with in vivo studies on animals using tritiated pimozide. In 5 patients pre-treated by a therapeutic dose of a cold neuroleptic (haloperidol) this difference in kinetics no longer existed. Moreover no kinetic difference is observed, either before or after haloperidol administration, between the frontal cortex (relatively low in dopaminergic receptors) and cerebellum. These results strongly suggest that pharmacokinetic phenomena directly related to the specific bonding of 11C-pimozide on the striatal dopaminergic receptors are observable on man in vivo. This specific bonding however remains quantitatively weak as compared with the strong non-specific bonding